Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | ELANE | P08246 | 2/20 | 0.55 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.52 |
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | CTSL | P07711 | 4/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312509 | 1.00 | ATM (0.56) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL6312134 | 1.00 | ATM (0.56) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL9383948 | 0.90 | CTSS (0.56) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL5724016 | 0.87 | ATM (0.57) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL15238327 | 0.87 | ATM (0.57) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL25465632 | 0.87 | TRPM8 (0.66) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL12798890 | 0.87 | ATM (0.57) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL2723524 | 0.87 | ATM (0.57) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL13489691 | 0.87 | ATM (0.57) | ATMELANETRPM8CTSKCTRB1 | |
| SCHEMBL6044625 | 0.86 | PSMB1 (0.58) | ATMELANETRPM8CTSKCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | claimed |
| US-20200283406-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | G1 THERAPEUTICS, INC. (US) | 2020-09-10 | — | — | US | claimed |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | US | claimed |
| US-10654831-B2 | Antiproliferative pyrimidine-based compounds | G1 THERAPEUTICS, INC. (US) | 2020-05-19 | — | — | US | claimed |
| US-10618905-B2 | Pyrimidine-based compounds for the treatment of cancer | G1 THERAPEUTICS, INC. (US) | 2020-04-14 | — | — | US | claimed |
| US-20190135784-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | claimed |
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | claimed |
| US-20160310499-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | G1 THERAPEUTICS, INC. | 2016-10-27 | — | — | US | claimed |
| US-20160108054-A1 | Lactam Kinase Inhibitors | PHARMACOSMOS HOLDING A/S (DK) | 2016-04-21 | — | — | US | claimed |
| US-9260442-B2 | Lactam kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2016-02-16 | — | — | US | claimed |
| US-20150299212-A1 | Tricyclic Lactams for Use in HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation | G1 THERAPEUTICS, INC. (US) | 2015-10-22 | — | — | US | claimed |
| US-20150297608-A1 | Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents | G1 THERAPEUTICS, INC. (US) | 2015-10-22 | — | — | US | claimed |
| US-20150297607-A1 | Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2015-10-22 | — | — | US | claimed |
| US-20140271466-A1 | HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-20140271460-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-8829012-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-09-09 | — | — | US | claimed |
| US-8822683-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | claimed |
| US-8598197-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2013-12-03 | — | — | US | claimed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | claimed |
| US-20130237533-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237534-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | ATM 415/4885ELANE 4040/4885TRPM8 4652/4885 |
| US-20160108054-A1 | Lactam Kinase Inhibitors | AKT1, MASTL, MAP3K19 | ATM 167/4885ELANE 3210/4885TRPM8 4534/4885 |
| US-20150297607-A1 | Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy | CDK6, CCNC, CDK4 | ATM 643/4885ELANE 2154/4885TRPM8 4687/4885 |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | ATM 1683/4885ELANE 4023/4885TRPM8 4556/4885 |
| US-20190135784-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | MKI67, TYMS, TYMP | ATM 1760/4885ELANE 4200/4885TRPM8 4384/4885 |
| US-20150299212-A1 | Tricyclic Lactams for Use in HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation | CDK4, CDK6, CDKL4 | ATM 1091/4885ELANE 3341/4885TRPM8 4712/4885 |
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | ATM 1105/4885ELANE 4606/4885TRPM8 4297/4885 |
| US-20140271466-A1 | HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation | RB1, CDK4, CDKN1A | ATM 1820/4885ELANE 2807/4885TRPM8 4166/4885 |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | ATM 1105/4885ELANE 4606/4885TRPM8 4297/4885 |
| US-20140271460-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | MKI67, PCNA, HRAS | ATM 3010/4885ELANE 353/4885TRPM8 4599/4885 |
| US-20130237533-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | ATM 415/4885ELANE 4040/4885TRPM8 4652/4885 |
| US-10654831-B2 | Antiproliferative pyrimidine-based compounds | MKI67, TYMS, TYMP | ATM 1760/4885ELANE 4200/4885TRPM8 4384/4885 |
| US-10618905-B2 | Pyrimidine-based compounds for the treatment of cancer | TYMS, TYMP, DPYD | ATM 1105/4885ELANE 4606/4885TRPM8 4297/4885 |
| US-20160310499-A1 | Highly Active Anti-Neoplastic and Anti-Proliferative Agents | MKI67, PCNA, HRAS | ATM 3010/4885ELANE 353/4885TRPM8 4599/4885 |
| US-20150297608-A1 | Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents | PCNA, TOP2A, CCNI | ATM 2471/4885ELANE 388/4885TRPM8 4644/4885 |
| US-20200283406-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | MKI67, TYMS, TYMP | ATM 1760/4885ELANE 4200/4885TRPM8 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.